CN114438149A - Method for synthesizing benzylisoquinoline alkaloid by constructing biological cascade reaction - Google Patents
Method for synthesizing benzylisoquinoline alkaloid by constructing biological cascade reaction Download PDFInfo
- Publication number
- CN114438149A CN114438149A CN202210056098.7A CN202210056098A CN114438149A CN 114438149 A CN114438149 A CN 114438149A CN 202210056098 A CN202210056098 A CN 202210056098A CN 114438149 A CN114438149 A CN 114438149A
- Authority
- CN
- China
- Prior art keywords
- zmts
- 29tfncs
- styab
- acid
- blpad
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930015408 benzyl-isoquinoline alkaloid Natural products 0.000 title claims abstract description 31
- 238000000034 method Methods 0.000 title claims abstract description 25
- 150000005516 benzylisoquinolines Chemical class 0.000 title claims abstract description 21
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 9
- 238000010523 cascade reaction Methods 0.000 title abstract description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 42
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960003638 dopamine Drugs 0.000 claims abstract description 21
- WZRCQWQRFZITDX-AWEZNQCLSA-N (S)-norcoclaurine Chemical compound C1=CC(O)=CC=C1C[C@H]1C2=CC(O)=C(O)C=C2CCN1 WZRCQWQRFZITDX-AWEZNQCLSA-N 0.000 claims abstract description 13
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 claims abstract description 11
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000013612 plasmid Substances 0.000 claims description 46
- 108090000790 Enzymes Proteins 0.000 claims description 37
- 102000004190 Enzymes Human genes 0.000 claims description 37
- 239000011942 biocatalyst Substances 0.000 claims description 31
- 239000000758 substrate Substances 0.000 claims description 26
- 241000588724 Escherichia coli Species 0.000 claims description 25
- 230000003197 catalytic effect Effects 0.000 claims description 22
- 239000013598 vector Substances 0.000 claims description 22
- 239000003054 catalyst Substances 0.000 claims description 20
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims description 16
- 230000035939 shock Effects 0.000 claims description 13
- 230000009466 transformation Effects 0.000 claims description 13
- 238000010276 construction Methods 0.000 claims description 9
- 238000001976 enzyme digestion Methods 0.000 claims description 9
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 9
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical class OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 claims description 9
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims description 8
- AFDXODALSZRGIH-QPJJXVBHSA-N (E)-3-(4-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 claims description 8
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 8
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 8
- HJBWJAPEBGSQPR-GQCTYLIASA-N 3,4-dimethoxycinnamic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1OC HJBWJAPEBGSQPR-GQCTYLIASA-N 0.000 claims description 8
- LZPNXAULYJPXEH-AATRIKPKSA-N 3-Methoxycinnamic acid Chemical compound COC1=CC=CC(\C=C\C(O)=O)=C1 LZPNXAULYJPXEH-AATRIKPKSA-N 0.000 claims description 8
- JZINNAKNHHQBOS-AATRIKPKSA-N 3-methylcinnamic acid Chemical compound CC1=CC=CC(\C=C\C(O)=O)=C1 JZINNAKNHHQBOS-AATRIKPKSA-N 0.000 claims description 8
- HJBWJAPEBGSQPR-UHFFFAOYSA-N DMCA Natural products COC1=CC=C(C=CC(O)=O)C=C1OC HJBWJAPEBGSQPR-UHFFFAOYSA-N 0.000 claims description 8
- 235000004883 caffeic acid Nutrition 0.000 claims description 8
- 229940074360 caffeic acid Drugs 0.000 claims description 8
- 235000013985 cinnamic acid Nutrition 0.000 claims description 8
- 229930016911 cinnamic acid Natural products 0.000 claims description 8
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims description 8
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 8
- 235000001785 ferulic acid Nutrition 0.000 claims description 8
- 229940114124 ferulic acid Drugs 0.000 claims description 8
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 8
- KKSDGJDHHZEWEP-UHFFFAOYSA-N m-hydroxycinnamic acid Natural products OC(=O)C=CC1=CC=CC(O)=C1 KKSDGJDHHZEWEP-UHFFFAOYSA-N 0.000 claims description 8
- AFDXODALSZRGIH-UHFFFAOYSA-N p-coumaric acid methyl ether Natural products COC1=CC=C(C=CC(O)=O)C=C1 AFDXODALSZRGIH-UHFFFAOYSA-N 0.000 claims description 8
- KKSDGJDHHZEWEP-SNAWJCMRSA-N trans-3-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=CC(O)=C1 KKSDGJDHHZEWEP-SNAWJCMRSA-N 0.000 claims description 8
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 8
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 7
- 238000009833 condensation Methods 0.000 claims description 5
- 230000002210 biocatalytic effect Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 108010016298 Styrene monooxygenase Proteins 0.000 claims description 3
- 241000194108 Bacillus licheniformis Species 0.000 claims description 2
- 241000589774 Pseudomonas sp. Species 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 238000010353 genetic engineering Methods 0.000 abstract description 3
- 241000193830 Bacillus <bacterium> Species 0.000 abstract description 2
- 210000001072 colon Anatomy 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 230000036983 biotransformation Effects 0.000 description 3
- 235000010378 sodium ascorbate Nutrition 0.000 description 3
- 229960005055 sodium ascorbate Drugs 0.000 description 3
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 3
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 3
- 102000004195 Isomerases Human genes 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 125000003798 L-tyrosyl group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241001524101 Rhodococcus opacus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
- C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/14—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (1.14.14)
- C12Y114/14011—Styrene monooxygenase (1.14.14.11)
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to a method for synthesizing benzylisoquinoline alkaloid by constructing biological cascade reaction. The invention reforms colon bacillus by genetic engineering means, constructs two new biocatalysis cascades, utilizes dopamine, p-coumaric acid derived from lignocellulose and analogues thereof to efficiently synthesize various benzyl isoquinoline alkaloids containing (S) -higenamine and (S) -norlapatine, the products have good enantioselectivity (more than or equal to 98% ee), and most of the benzyl isoquinoline alkaloids have the concentration more than 1 g.L‑1。
Description
Technical Field
The invention belongs to the field of biocatalysts, and particularly relates to a method for synthesizing benzylisoquinoline alkaloid by constructing a biological cascade reaction.
Background
Benzylisoquinoline alkaloids (BIAs) are plant-specific metabolites, consisting of about 2500 compounds in a large family. These compounds are receiving increasing attention for their various biological activities, such as antibacterial, anti-inflammatory, antiviral and anti-plasmodium activities. Typically, BIAs, such as noscapine, morphine and papaverine, are used as cough suppressants, narcotic analgesics and muscle relaxants, respectively. In addition, some BIAs were identified as entry inhibitors against the novel virus SARS-CoV-2, which is the major factor responsible for the 2019 coronavirus disease (COVID-19). Therefore, efficient synthesis of alkaloids is of great significance.
Industrially, the synthesis of BIAs also relies mainly on methods of extraction from plant tissues or chemical synthesis. However, conventional extraction methods have several limitations, including low efficiency, high cost, and long time consumption, and chemical synthesis also faces challenges, such as structural complexity and the use of environmentally unfriendly reagents. In addition, the rapid development of synthetic biology provides a new idea for the synthesis of BIAs. The most commonly used method is de novo synthesis of monosaccharides as starting material by constructing a heterologous pathway in a microorganism such as Saccharomyces cerevisiae or E.coli. This approach aims to mimic the natural biosynthetic pathways in plants, but these pathways often involve multistep reactions, multiple enzymes, resulting in lower synthesis efficiency. In addition, the method of in vitro enzyme cascade is also a more common approach in recent years. The method usually takes an L-tyrosine derivative as a substrate, and shows huge potential in the aspects of product yield and stereoselectivity. However, this method involves purification and preparation of multiple enzymes, often at a high cost. The chemoenzymatic cascade offers another approach to the synthesis of complex BIAs, especially BIAs with high stereoselectivity, but this approach often faces the challenge of incompatibility of the conditions required for chemical and enzymatic conversion.
Disclosure of Invention
The invention aims to solve the problems in the prior art and provides a method for synthesizing benzylisoquinoline alkaloid by constructing biological cascade reaction. The invention synthesizes benzyl isoquinoline alkaloid by constructing a biological catalytic cascade to catalyze p-coumaric acid derivatives and dopamine.
The invention reforms colon bacillus by genetic engineering means, constructs two new biocatalysis cascades, utilizes dopamine, p-coumaric acid derived from lignocellulose and analogues thereof to efficiently synthesize various benzyl isoquinoline alkaloids containing (S) -higenamine and (S) -norlapatine, the products have good enantioselectivity (more than or equal to 98% ee), and most of the benzyl isoquinoline alkaloids have the concentration more than 1 g.L-1。
The purpose of the invention can be realized by the following scheme:
the invention provides a method for synthesizing benzylisoquinoline alkaloid by constructing biological cascade reaction, which comprises the following steps:
s1, transforming escherichia coli, and constructing a decarboxylation-epoxy-isomerization-condensation biocatalysis cascade to obtain a biocatalyst;
s2, synthesizing the benzylisoquinoline alkaloid by taking dopamine and p-coumaric acid or derivatives thereof as catalytic substrates through a biocatalyst.
As an embodiment of the invention, the p-coumaric acid derivative comprises one of ferulic acid, caffeic acid, cinnamic acid, 3-hydroxycinnamic acid, 3-methyl cinnamic acid, 3-methoxy cinnamic acid, 4-methoxy cinnamic acid and 3, 4-dimethoxy cinnamic acid.
As one embodiment of the present invention, the benzylisoquinoline alkaloids include (S) -norcoclaurine, (S) -norlauradine, (S) -1, (S) -2, (S) -3, (S) -4, (S) -5, (S) -6, (S) -7;
(S) -7 structural formula is as follows:
as an embodiment of the invention, the construction of the biocatalytic cascade decarboxylation-epoxy-isomerisation-condensation is achieved by overexpressing in e.coli one or more of the decarboxylase BLPad derived from Bacillus licheniformis CGMCC7172, the styrene monooxygenase StyAB derived from Pseudomonas sp.strain VLB120, the epoxide isomerase RostyC derived from Rhodococcus opacus 1CP, the norcoculinine synthase mutant Δ 29TfNCS derived from thalmictrum flavum, the decarboxylase AnPad derived from Aspergillus niger (coding genes fdc and pad). The enzymes used in the present invention are known enzymes and can be obtained from literature reports or from NCBI. The invention constructs a catalytic cascade of decarboxylation-epoxy-isomerization-condensation by overexpressing one or more of decarboxylase, styrene monooxygenase, epoxide isomerase and higenamine synthetase in escherichia coli to prepare the biocatalyst.
In the process, four biocatalysts ZMTS 1-4 are constructed to catalyze dopamine and p-coumaric acid to synthesize (S) -higenamine, the optimal biocatalyst is selected to further catalyze dopamine and caffeic acid to synthesize (S) -norloratadine, and dopamine and ferulic acid are catalyzed to synthesize a non-natural benzyl isoquinoline alkaloid; a biocatalyst ZMTS 5 is constructed to catalyze dopamine and p-coumaric acid derivatives (cinnamic acid, 3-hydroxycinnamic acid, 3-methyl cinnamic acid, 3-methoxy cinnamic acid, 4-methoxy cinnamic acid and 3, 4-dimethoxy cinnamic acid) to successfully synthesize 6 unnatural benzylisoquinoline alkaloids.
As an embodiment of the present invention, the catalyst is constructed by introducing two combinations of plasmids pET28a-StyAB-RostyC-7-BLPad, pA7a- Δ 29TfNCS, pB7c- Δ 29TfNCS, pET28a-StyAB-RostyC, pA7a-BLPad-7- Δ 29TfNCS, pB7c-BLPad-7- Δ 29TfNCS, pET28a-StyAB-RostyC-7-AnPad, and pA7a- Δ 29TfNCS into E.coli. Plasmid pET28a-StyAB-RostyC-7-BLpad 7 shows the T7 promoter, to which the T7 promoter was added before the BLPad gene. Plasmid pB7c-BLPad-7- Δ 29TfNCS 7 shows the T7 promoter, with the addition of the T7 promoter in front of the Δ 29TfNCS gene. In plasmid pET28a-StyAB-RostyC-7-AnPad 7 represents the T7 promoter, the T7 promoter was added before fdc and the pad gene. The plasmids used in the present invention are known plasmids and can be obtained from reported literature.
As an embodiment of the present invention, plasmid pET28a-StyAB-RostyC-7-BLPad was constructed by enzymatically ligating BLPad, StyAB and RostyC into vector pET28 a.
As an embodiment of the present invention, plasmid pET28a-StyAB-RostyC is constructed by enzymatically ligating StyAB and RostyC into vector pET28 a.
As an embodiment of the invention, the plasmid pA7 a-delta 29TfNCS is constructed by enzymatically ligating delta 29TfNCS into vector pA7 a.
As an embodiment of the invention, the plasmid pB7 c-delta 29TfNCS is constructed by enzymatically ligating delta 29TfNCS into the vector pB7 c.
As an embodiment of the invention, the plasmid pA7a-BLPad-7- Δ 29TfNCS is constructed by enzymatically ligating BLPad and Δ 29TfNCS into vector pA7 a.
As an embodiment of the invention, the plasmid pB7 c-BLPad-7-. DELTA.29 TfNCS was constructed by enzymatically ligating BLPad and DELTA.29 TfNCS into the vector pB7 c.
As an embodiment of the invention, the plasmid pET28a-StyAB-RostyC-7-AnPad was constructed by enzymatically ligating AnPad, StyAB and RostyC into the vector pET28 a.
As an embodiment of the invention, the plasmid pA7 a-delta 29TfNCS is constructed by enzymatically ligating delta 29TfNCS into vector pA7 a.
As an embodiment of the invention, the biocatalysts include biocatalysts ZMTS 1, ZMTS 2, ZMTS 3, ZMTS 4, ZMTS 5; the biocatalyst, ZMTS 1, was prepared from plasmids pET28a-StyAB-RostyC-7-BLPad and pA7a- Δ 29TfNCS by heat shock transformation into E.coli; ZMTS 2 was prepared from plasmids pET28a-StyAB-RostyC-7-BLPad and pB7 c-. DELTA.29 TfNCS by heat shock transformation into E.coli; ZMTS 3 was made from plasmids pET28a-StyAB-RostyC and pA7 a-BLPad-7-. DELTA.29 TfNCS by heat shock transformation into E.coli; ZMTS 4 was prepared from plasmids pET28a-StyAB-RostyC and pB7 c-BLPad-7-. DELTA.29 TfNCS by heat shock transformation into E.coli; ZMTS 5 was constructed from plasmid pET28 a-StyAB-RostyrC-7-AnPad and pA7 a-. DELTA.29 TfNCS, which were introduced into E.coli in combination.
As one embodiment of the invention, when the catalytic substrate of the catalyst ZMTS 1-4 is p-coumaric acid, the product is (S) -higenamine; when the catalytic substrate of the catalyst ZMTS 1-4 is ferulic acid, the product is (S) -1; when the catalytic substrate of the catalyst ZMTS 1-4 is caffeic acid, the product is (S) -total norlaudane alkali.
As an embodiment of the present invention, when the catalytic substrate of the catalyst ZMTS 5 is cinnamic acid, the product is (S) -2; when the catalytic substrate of the catalyst ZMTS 5 is 3-hydroxycinnamic acid, the product is (S) -3; when the catalytic substrate of the catalyst ZMTS 5 is 3-methyl cinnamic acid, the product is (S) -4; when the catalytic substrate of the catalyst ZMTS 5 is 3-methoxycinnamic acid, the product is (S) -5; when the catalytic substrate of the catalyst ZMTS 5 is 4-methoxycinnamic acid, the product is (S) -6; when the catalytic substrate of the catalyst ZMTS 5 is 3, 4-dimethoxycinnamic acid, the product is (S) -7.
Compared with the prior art, the invention has the following beneficial effects:
(1) a new biocatalysis cascade is constructed by means of genetic engineering, a high-efficiency biocatalyst is obtained, and substrates dopamine and p-coumaric acid derivatives can be rapidly catalyzed to synthesize various benzylisoquinoline alkaloids containing (S) -higenamine.
(2) The constructed biocatalyst is utilized to realize the high-efficiency utilization of aromatic compounds (p-coumaric acid and derivatives thereof) derived from lignocellulose through biotransformation in the presence of dopamine, and the method has more advantages compared with de novo synthesis, in vitro enzyme cascade and chemical enzymatic cascade which take glucose as a substrate.
(3) The yield of the obtained target compound is mostly over gram, and the target compound has good enantioselectivity (more than or equal to 98% ee), and has great application potential.
Drawings
Other features, objects and advantages of the invention will become more apparent upon reading of the detailed description of non-limiting embodiments with reference to the following drawings:
FIG. 1 is a schematic diagram of the reaction of constructing a biocatalytic cascade for catalyzing p-coumaric acid derivatives and dopamine to synthesize benzylisoquinoline alkaloid;
FIG. 2 is a schematic diagram of the construction of biocatalysts for catalyzing the synthesis of BIAs from p-coumaric acid derivatives and dopamine;
FIG. 3 is a graph showing the concentration of (S) -higenamine synthesized by different biocatalysts catalyzing p-coumaric acid and dopamine.
Detailed Description
The invention is described in detail below with reference to the figures and specific embodiments. The following examples, which are set forth to provide a detailed description of the invention and a detailed description of the operation, will help those skilled in the art to further understand the present invention. It should be noted that the protection scope of the present invention is not limited to the following embodiments, and several modifications and improvements made on the premise of the idea of the present invention belong to the protection scope of the present invention.
Example 1
(1) Construction of a biocatalytic cascade for catalysis of coumaric acid derivatives (p-coumaric acid, ferulic acid and caffeic acid) and dopamine (schematic construction shown in FIG. 1)
Plasmids pET28a-StyAB-RostyC-7-BLPad (7 represents T7 promoter, T7 promoter is added before BLpad gene), pA7 a-delta 29TfNCS, pB7 c-delta 29TfNCS, pET28a-StyAB-RostyC, pA7 a-BLPad-7-delta 29TfNCS and pB7 c-BLPad-7-delta 29TfNCS (7 represents T7 promoter, T7 promoter is added before delta 29TfNCS gene) are constructed, and the two are combined and introduced into Escherichia coli to construct 4 biocatalysts ZMTS 1, ZMTS 2, ZMTS 3 and ZMTS 4 (construction schematic diagram is shown in FIG. 2). The specific method comprises the following steps:
plasmids pET28a-StyAB-RostyC-7-BLPad and pET28a-StyAB-RostyC were constructed by ligating BLPad, StyAB and RostyC into vector pET28a by digestion; the delta 29TfNCS enters vectors pA7a and pB7c through enzyme digestion connection to respectively construct plasmids pA7 a-delta 29TfNCS and pB7 c-delta 29 TfNCS; the BLPad and the delta 29TfNCS enter a vector pA7a through enzyme digestion connection to construct a plasmid pA7 a-BLPad-7-delta 29 TfNCS; plasmid pB7c-BLPad-7- Δ 29TfNCS was constructed by enzymatic ligation of BLPad and Δ 29TfNCS into vector pB7 c.
The above biocatalyst ZMTS 1 was prepared from plasmids pET28a-StyAB-RostyC-7-BLPad and pA7 a-. DELTA.29 TfNCS by heat shock transformation into E.coli; ZMTS 2 was prepared from plasmids pET28a-StyAB-RostyC-7-BLPad and pB7 c-. DELTA.29 TfNCS by heat shock transformation into E.coli; ZMTS 3 was made from plasmids pET28a-StyAB-RostyC and pA7 a-BLPad-7-. DELTA.29 TfNCS by heat shock transformation into E.coli; ZMTS 4 was prepared from plasmids pET28a-StyAB-RostyC and pB7 c-BLPad-7-. DELTA.29 TfNCS by heat shock transformation into E.coli.
(2) Biotransformation (schematic concentration of the synthesized product is shown in FIG. 3)
Respectively inoculating the prepared biocatalyst ZMTS 1-4 into 2mL LB to activate seeds, transferring the activated seeds into 100mL LB according to the ratio of 1:100 after 10-12h at 37 ℃, and waiting for OD600When the concentration reaches 0.6, adding inducer IPTG to final concentration of 0.5mM, inducing at 25 deg.C for 5 hr, centrifuging at 4 deg.C for 10min at 4000g, collecting thallus, and resuspending in HEPES buffer (50mM, pH 7.0, OD)60030), 10mM p-coumaric acid, 10mM dopamine, 10g/L glucose and 10mM sodium ascorbate were added and transformed at 37 ℃ for 1 h. The results are shown in the figure, ZMTS 1-4 synthesizes 8.7, 6.8, 8.4 and 7.5mM of (S) -higenamine respectively. The above conditions were repeated to prepare again biocatalyst ZMTS 1 resuspended in HEPES buffer (50mM, pH 7.0, OD)60030), 5mM (ferulic acid or caffeic acid), 5mM dopamine, 10g/L glucose and 5mM sodium ascorbate were added, and transformed at 37 ℃ for 2 h. After the reaction, 1.8mM of (S) -1 and 2.3mM of (S) -norlapatine were obtained (see Table 1).
TABLE 1
Table 1 biocatalyst ZMTS 1 catalyzes the synthesis of corresponding BIAs from substrates (ferulic acid and caffeic acid) and dopamine.
Example 2
(1) Constructing a biological catalysis cascade for catalyzing p-coumaric acid derivatives (cinnamic acid, 3-hydroxycinnamic acid, 3-methyl cinnamic acid, 3-methoxy cinnamic acid, 4-methoxy cinnamic acid and 3, 4-dimethoxy cinnamic acid) and dopamine (the construction schematic diagram is shown in figure 1)
Construction of plasmid pET28a-StyAB-RostyC-7-AnPad (7 represents T7 promoter, T7 promoter was added before fdc and pad gene) and pA7 a-delta 29TfNCS were combined in pairs and introduced into E.coli to construct ZMTS 5 (construction scheme is shown in FIG. 2). The specific method comprises the following steps:
the AnPad, StyAB and RostyC are connected into a vector pET28a through enzyme digestion to construct a plasmid pET28 a-StyAB-RostyC-7-AnPad; plasmid pA7a- Δ 29TfNCS was constructed by enzymatic ligation of Δ 29TfNCS into vector pA7 a.
The above biocatalyst, ZMTS 5, was prepared from plasmids pET28a-StyAB-RostyC-7-AnPad and pA7 a-. DELTA.29 TfNCS by heat shock transformation into E.coli.
(2) Biotransformation
Inoculating the prepared biocatalyst ZMTS 5 into 2mL LB to activate seeds, transferring into 100mL LB at 37 deg.C for 10-12h according to the ratio of 1:100, adding inducer IPTG to final concentration of 0.5mM when OD600 reaches 0.6, inducing at 25 deg.C for 5h, centrifuging at 4 deg.C for 10min at 4000g, collecting thallus, and resuspending in HEPES buffer solution (50mM, pH 7.0, OD 7.0)60030), 10mM p-coumaric acid derivative substrates (cinnamic acid, 3-hydroxycinnamic acid, 3-methylcinnamic acid, 3-methoxycinnamic acid, 4-methoxycinnamic acid, and 3, 4-dimethoxycinnamic acid), 10mM dopamine, 10g/L glucose, and 10mM sodium ascorbate were added, and the conversion was carried out at 37 ℃ for 2 h. The reaction results are shown in Table 2, and 9.1, 3.3, 7.1, 8.4, 7.7 and 3.2mM of (S) -2, (S) -3, (S) -4, (S) -5, (S) -6 and (S) -7 were synthesized, respectively.
TABLE 2
TABLE 2 biocatalysts catalyze the synthesis of corresponding BIAs from substrates (cinnamic acid, 3-hydroxycinnamic acid, 3-methyl cinnamic acid, 3-methoxy cinnamic acid, 4-methoxy cinnamic acid and 3, 4-dimethoxy cinnamic acid) and dopamine.
The foregoing description of specific embodiments of the present invention has been presented. It is to be understood that the present invention is not limited to the specific embodiments described above, and that various changes and modifications may be made by one skilled in the art within the scope of the appended claims without departing from the spirit of the invention.
Claims (10)
1. A method for synthesizing benzylisoquinoline alkaloids by constructing a biological cascade, comprising the steps of:
s1, transforming escherichia coli, and constructing a decarboxylation-epoxy-isomerization-condensation biocatalysis cascade to obtain a biocatalyst;
s2, synthesizing the benzylisoquinoline alkaloid by taking dopamine and p-coumaric acid or derivatives thereof as catalytic substrates through a biocatalyst.
2. The method of claim 1, wherein the p-coumaric acid derivative comprises one of ferulic acid, caffeic acid, cinnamic acid, 3-hydroxycinnamic acid, 3-methylcinnamic acid, 3-methoxycinnamic acid, 4-methoxycinnamic acid, 3, 4-dimethoxycinnamic acid.
3. The method of claim 1, wherein the benzylisoquinoline alkaloids comprise (S) -norcoclaurine, (S) -norlauradine, (S) -1, (S) -2, (S) -3, (S) -4, (S) -5, (S) -6, (S) -7;
(S) -7 structural formula is as follows:
4. the method according to claim 1, characterized in that the construction of the biocatalytic cascade of decarboxylation-epoxy-isomerisation-condensation is achieved by overexpressing in e.coli one or more of the decarboxylase BLPad derived from Bacillus licheniformis CGMCC7172, the styrene monooxygenase StyAB derived from Pseudomonas sp.
5. The method of claim 1, wherein the catalyst is constructed by introducing two combinations of plasmids pET28a-StyAB-RostyC-7-BLPad, pA7a- Δ 29TfNCS, pB7c- Δ 29TfNCS, pET28a-StyAB-RostyC, pA7a-BLPad-7- Δ 29TfNCS, pB7c-BLPad-7- Δ 29TfNCS, pET28a-StyAB-RostyC-7-AnPad, and pA7a- Δ 29TfNCS into E.coli.
6. The method of claim 5, wherein plasmid pET28a-StyAB-RostyC-7-BLPad is constructed by enzymatically ligating BLPad, StyAB and RostyC into vector pET28 a; the plasmid pET28 a-StyAB-RostyrC is constructed by connecting StyAB and RostyrC into a vector pET28a through enzyme digestion; the plasmid pA7 a-delta 29TfNCS is constructed by allowing delta 29TfNCS to enter a vector pA7a through enzyme digestion and ligation; the plasmid pB7 c-delta 29TfNCS is constructed by allowing delta 29TfNCS to enter a vector pB7c through enzyme digestion and connection; the plasmid pA7 a-BLPad-7-delta 29TfNCS is constructed by connecting BLPad and delta 29TfNCS into a vector pA7a through enzyme digestion; the plasmid pB7 c-BLPad-7-delta 29TfNCS is constructed by connecting BLPad and delta 29TfNCS into a vector pB7c through enzyme digestion; the plasmid pET28a-StyAB-RostyC-7-AnPad is constructed by connecting AnPad, StyAB and RostyC into a vector pET28a through enzyme digestion; the plasmid pA7 a-delta 29TfNCS was constructed by enzymatically ligating delta 29TfNCS into vector pA7 a.
7. The process of claim 1 wherein said biocatalysts comprise biocatalyst ZMTS 1, biocatalyst ZMTS 2, biocatalyst ZMTS 3, biocatalyst ZMTS 4, biocatalyst ZMTS 5.
8. The process of claim 7, wherein the biocatalyst ZMTS 1 is prepared from plasmids pET28a-StyAB-RostyC-7-BLPad and pA7a- Δ 29TfNCS by heat shock transformation into E.coli; ZMTS 2 was prepared from plasmids pET28a-StyAB-RostyC-7-BLPad and pB7 c-. DELTA.29 TfNCS by heat shock transformation into E.coli; ZMTS 3 was made from plasmids pET28a-StyAB-RostyC and pA7 a-BLPad-7-. DELTA.29 TfNCS by heat shock transformation into E.coli; ZMTS 4 was prepared from plasmids pET28a-StyAB-RostyC and pB7 c-BLPad-7-. DELTA.29 TfNCS by heat shock transformation into E.coli; ZMTS 5 was constructed from plasmid pET28 a-StyAB-RostyrC-7-AnPad and pA7 a-. DELTA.29 TfNCS, which were introduced into E.coli in combination.
9. The method of claim 6 wherein when the catalytic substrate of catalyst ZMTS 1-ZMTS 4 is p-coumaric acid, the product is (S) -higenamine; when the catalytic substrate of the catalyst ZMTS 1-4 is ferulic acid, the product is (S) -1; when the catalytic substrate of the catalyst ZMTS 1-4 is caffeic acid, the product is (S) -total norlaudane alkali.
10. The process of claim 6 wherein when the catalytic substrate of ZMTS 5 catalyst is cinnamic acid, the product is (S) -2; when the catalytic substrate of the catalyst ZMTS 5 is 3-hydroxycinnamic acid, the product is (S) -3; when the catalytic substrate of the catalyst ZMTS 5 is 3-methyl cinnamic acid, the product is (S) -4; when the catalytic substrate of the catalyst ZMTS 5 is 3-methoxycinnamic acid, the product is (S) -5; when the catalytic substrate of the catalyst ZMTS 5 is 4-methoxycinnamic acid, the product is (S) -6; when the catalytic substrate of the catalyst ZMTS 5 is 3, 4-dimethoxycinnamic acid, the product is (S) -7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210056098.7A CN114438149A (en) | 2022-01-18 | 2022-01-18 | Method for synthesizing benzylisoquinoline alkaloid by constructing biological cascade reaction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210056098.7A CN114438149A (en) | 2022-01-18 | 2022-01-18 | Method for synthesizing benzylisoquinoline alkaloid by constructing biological cascade reaction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114438149A true CN114438149A (en) | 2022-05-06 |
Family
ID=81367406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210056098.7A Pending CN114438149A (en) | 2022-01-18 | 2022-01-18 | Method for synthesizing benzylisoquinoline alkaloid by constructing biological cascade reaction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114438149A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110191912A1 (en) * | 2000-04-26 | 2011-08-04 | Nickolai Alexandrov | Promoter, promoter control elements, and combinations, and uses thereof |
| CN107614688A (en) * | 2015-05-04 | 2018-01-19 | 小利兰·斯坦福大学托管委员会 | Produce the microorganism and its preparation and application of benzyl isoquinoline alkaloid (BIA) precursor |
| CN111108204A (en) * | 2017-07-24 | 2020-05-05 | 国立研究开发法人理化学研究所 | Decarboxylase and method for producing unsaturated hydrocarbon compound using same |
| CN112481336A (en) * | 2020-11-27 | 2021-03-12 | 上海交通大学 | Method for biosynthesizing high value-added compound by utilizing lignocellulose derivative |
-
2022
- 2022-01-18 CN CN202210056098.7A patent/CN114438149A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110191912A1 (en) * | 2000-04-26 | 2011-08-04 | Nickolai Alexandrov | Promoter, promoter control elements, and combinations, and uses thereof |
| CN107614688A (en) * | 2015-05-04 | 2018-01-19 | 小利兰·斯坦福大学托管委员会 | Produce the microorganism and its preparation and application of benzyl isoquinoline alkaloid (BIA) precursor |
| CN111108204A (en) * | 2017-07-24 | 2020-05-05 | 国立研究开发法人理化学研究所 | Decarboxylase and method for producing unsaturated hydrocarbon compound using same |
| CN112481336A (en) * | 2020-11-27 | 2021-03-12 | 上海交通大学 | Method for biosynthesizing high value-added compound by utilizing lignocellulose derivative |
Non-Patent Citations (4)
| Title |
|---|
| BENJAMIN R. LICHMAN等: "Structural Evidence for the Dopamine-First Mechanism of Norcoclaurine Synthase", BIOCHEMISTRY, vol. 56, no. 40, pages 5274 - 5277 * |
| GODWIN A ALEKU等: "Synthetic Enzyme-Catalyzed CO2 Fixation Reactions", CHEMSUSCHEM, vol. 14, no. 8, pages 1781 - 1804 * |
| JUAN D. GUZMAN等: "Tetrahydroisoquinolines affect the whole-cell phenotype of Mycobacterium tuberculosis by inhibiting the ATP-dependent MurE ligase", J ANTIMICROB CHEMOTHER, vol. 70, pages 1691 - 1703 * |
| KARL A P PAYNE等: "New cofactor supports α,β-unsaturated acid decarboxylation via 1,3-dipolar cycloaddition", NATURE, vol. 522, no. 7557, pages 497 - 501, XP055393569, DOI: 10.1038/nature14560 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Enzymatic synthesis of an ezetimibe intermediate using carbonyl reductase coupled with glucose dehydrogenase in an aqueous-organic solvent system | |
| Panke et al. | Production of enantiopure styrene oxide by recombinant Escherichia coli synthesizing a two‐component styrene monooxygenase | |
| Wu et al. | Enzymatic promiscuity for organic synthesis and cascade process | |
| He et al. | Highly efficient synthesis of ethyl (S)-4-chloro-3-hydroxybutanoate and its derivatives by a robust NADH-dependent reductase from E. coli CCZU-K14 | |
| CN106868030B (en) | Recombinant vector, engineering bacterium containing recombinant vector and application of recombinant vector in production of alpha-ketoglutaric acid | |
| Zhao et al. | Construction of biocatalytic cascades for the synthesis of benzylisoquinoline alkaloids from p-coumaric acid derivatives and dopamine | |
| Khobragade et al. | Synthesis of sitagliptin intermediate by a multi-enzymatic cascade system using lipase and transaminase with benzylamine as an amino donor | |
| EP3255147A1 (en) | Immobilized cell and preparation method thereof | |
| CN110628841A (en) | Novel method for synthesizing key intermediate of dextromethorphan through enzyme catalysis asymmetry | |
| Tan et al. | Recent advances in biocatalytic derivatization of L-tyrosine | |
| CN113355299B (en) | Ketoacid reductase, gene, engineering bacterium and application in synthesis of chiral aromatic 2-hydroxy acid | |
| See et al. | Recent developments in oxidative biocatalytic cascades | |
| CN113293151B (en) | Short-chain dehydrogenase mutants and uses thereof | |
| Qin et al. | Production of biobased ethylbenzene by cascade biocatalysis with an engineered photodecarboxylase | |
| Huo et al. | Hydroxytyrosol production from l-DOPA by engineered Escherichia coli co-expressing l-amino acid deaminase, α-keto acid decarboxylase, aldehyde reductase and glucose dehydrogenase with NADH regeneration | |
| CN114438149A (en) | Method for synthesizing benzylisoquinoline alkaloid by constructing biological cascade reaction | |
| JP5992142B2 (en) | Enzymatic reduction of α- and β-dehydroamino acids using enoate reductase | |
| CN112708641A (en) | Chemical-enzymatic synthesis method of tomoxetine | |
| Chen et al. | Efficient synthesis of Ibrutinib chiral intermediate in high space-time yield by recombinant E. coli co-expressing alcohol dehydrogenase and glucose dehydrogenase | |
| CN113755415B (en) | Novel recombinant microorganism with NMN synthesis path and production method thereof | |
| Jiang et al. | One pot enzyme-catalyzed cascade benefit systems | |
| WO2014146242A1 (en) | Enzymatic preparation method for oxidized coenzyme ii | |
| Liu et al. | Biocatalytic Hydrogen-Borrowing Cascade in Organic Synthesis | |
| Cheng | Enzyme-based Organic Synthesis | |
| CN117363667B (en) | Use of imine reductase in preparation of dapoxetine intermediate and/or dapoxetine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220506 |
|
| WD01 | Invention patent application deemed withdrawn after publication |